Skip to main content

Table 3 Correlations between peripheral lymphocyte subsets and clinicopathological features in ovarian

From: Peripheral lymphocyte populations in ovarian cancer patients and correlations with clinicopathological features

Variables

Histology

FIGO stage

Platinum Response

HGSC

CCC

P

Early (I + II)

Late (III + IV)

P

Sensitive

Resistant

P

CD3+ T cells (%)

66.88 ± 9.46

73.27 ± 8.07

0.053

66.56 ± 10.91

67.27 ± 9.21

0.763

66.99 ± 7.44

66.07 ± 15.14

0.835

CD3+CD4+T cells (%)

38.43 ± 9.22

42.18 ± 7.65

0.241

39.19 ± 8.64

38.47 ± 9.18

0.748

39.48 ± 7.84

36.67 ± 12.59

0.458

CD3+CD8+ T cells (%)

26.49 ± 8.90

28.82 ± 10.94

0.464

26.73 ± 11.27

26.87 ± 8.93

0.951

27.63 ± 8.61

29.39 ± 12.85

0.565

CD8+CD28+ T cells (%)

7.07 ± 2.80

8.51 ± 2.88

0.145

7.70 ± 2.52

7.23 ± 2.83

0.489

7.53 ± 2.90

6.67 ± 3.58

0.374

NK cells (CD3CD56+) (%)

18.37 ± 8.95

14.30 ± 6.96

0.188

17.89 ± 10.08

18.15 ± 8.88

0.908

17.15 ± 7.34

21.64 ± 15.33

0.323

Tregs (CD4+CD25+CD127)(%)

12.91 ± 3.22

13.79 ± 4.14

0.445

13.20 ± 3.07

13.02 ± 3.26

0.830

12.50 ± 2.63

12.47 ± 4.24

0.976

B cells (CD19+) (%)

12.40 ± 5.24

10.20 ± 2.15

0.024

14.99 ± 5.81

12.13 ± 5.05

0.028

13.61 ± 6.03

9.86 ± 4.07

0.014

CD4/CD8 ratio

1.67 ± 0.85

1.74 ± 0.91

0.818

2.40 ± 2.69

1.64 ± 0.82

0.253

1.88 ± 1.83

1.55 ± 1.00

0.386

  1. Abbreviations: HGSC High-Grade Serous Carcinoma, CCC Clear Cell Carcinoma, FIGO The International Federation of Gynecology and Obstetrics